Key result
Child-parent cascade screening yields a ~99% genetic confirmation rate but no difference in CVD prevalence.
Why the study?
Cascade screening of parents of children with familial hypercholesterolemia could reduce cardiovascular disease burden through timely diagnosis, prompting evaluation of a pilot screening program in Slovenia.
Does a child-parent cascade screening program successfully identify familial hypercholesterolemia in parents of affected index children?
Observational (n=138)
Does a child-parent cascade screening program successfully identify familial hypercholesterolemia in parents of affected index children?
A child-parent cascade screening program is highly successful and feasible for identifying familial hypercholesterolemia in parents, potentially enabling earlier diagnosis and reducing cardiovascular disease burden.
Cascade screening supports high-yield FH identification in parents; observational data leave open impact on CVD prevalence.
BACKGROUND AND AIMS: Cascade familial hypercholesterolemia (FH) screening of parents could reduce the burden cardiovascular disease (CVD) in relatives of index cases by enabling timely diagnosis of FH. Here, we present the positive outcomes of the pilot child-parent cascade screening program in Slovenia. METHODS: One hundred and thirty-eight parents from 123 families of an index child with genetically confirmed FH were randomly included in the pilot child-parent cascade screening program. Index children were identified through the universal FH screening program in preschool children. Genetic testing using Sanger sequencing was performed for cascade screening to detect (likely) pathogenic variants, previously confirmed in the index child. RESULTS: The success rate of confirming a (likely) pathogenic variant was 77.2 % when the first parent, preferably with higher total cholesterol levels, was tested, and reached 99.1 % when the variant was identified in the first tested parent or when both parents were tested. In the minority of cases (13.8 %), parents had had a clinical diagnosis of FH prior to their child and these had somewhat higher prevalence of CVD compared to parents that were diagnosed after their index child through the pilot program (12.5 % vs. 4.3 %; p = 0.382). CONCLUSIONS: In conclusion, the presented pilot child-parent cascade screening program is feasible in clinical practice and shows a high success rate in identifying parents with FH. Parents diagnosed through the program appeared to have a lower prevalence of CVD. However, larger cohorts are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Šikonja et al. (2025) conducted an observational in Familial hypercholesterolemia (n=138). Child-parent cascade screening vs. Parents with a prior clinical diagnosis of FH was evaluated on Prevalence of cardiovascular disease (p=0.382). Child-parent cascade screening yielded a 99.1% genetic confirmation rate, with newly diagnosed parents having a 4.3% CVD prevalence versus 12.5% in previously diagnosed parents (p=0.382).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: